参考文献/References:
[1] Ruopp NF,Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension:a review[J]. JAMA,2022,327(14):1379-1391.
[2] Xin Z,Wang J,Li S,et al. A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension[J]. Clin Exp Hypertens,2022,44(2):175-180.
[3] Frost A,Badesch D,Gibbs JSR,et al. Diagnosis of pulmonary hypertension[J]. Eur Respir J,2019, 53(1):1801904.
[4] Hoeper MM,Ghofrani HA,Grünig E,et al. Pulmonary Hypertension[J]. Dtsch Arztebl Int, 2017,114(5):73-84.
[5] Liang S,Desai AA,Black SM,et al. Cytokines,chemokines,and inflammation in pulmonary arterial hypertension[J]. Adv Exp Med Biol,2021,1303:275-303.
[6] Bello-klein A,Mancardi D,Araujo AS,et al. Role of redox homeostasis and inflammation in the pathogenesis of pulmonary arterial hypertension[J]. Curr Med Chem,2018,25(11):1340-1351.
[7] Wu WH,Yuan P,Zhang SJ,et al. Impact of pituitary-gonadal axis hormones on pulmonary arterial hypertension in men[J]. Hypertension,2018,72(1):151-158.
[8] Dromparis P,Sutendra G,Michelakis ED. The role of mitochondria in pulmonary vascular remodeling[J]. J Mol Med (Berl),2010,88(10):1003-1010.
[9] Liu G,Fu D,Tian H,et al. The mechanism of ions in pulmonary hypertension[J]. Pulm Circ, 2021,11(1):2045894020987948.
[10] Prins KW,Archer SL,Pritzker M,et al. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension[J]. J Heart Lung Transplant,2018,37(3):376-384.
[11] D’alessandro A,El Kasmi KC,Plecitá-hlavatá L,et al. Hallmarks of pulmonary hypertension:mesenchymal and inflammatory cell metabolic reprogramming[J]. Antioxid Redox Signal,2018,28(3):230-250.
[12] Evans CE,Zhao YY. Molecular basis of nitrative stress in the pathogenesis of pulmonary hypertension[J]. Adv Exp Med Biol,2017,967:33-45.
[13] Luo L,Hong X,Diao B,et al. Sulfur dioxide attenuates hypoxia-induced pulmonary arteriolar remodeling via Dkk1/Wnt signaling pathway[J]. Biomed Pharmacother,2018,106:692-698.
[14] Mondejar-Parre?o G,Cogolludo A,Perez-Vizcaino F. Potassium (K+) channels in the pulmonary vasculature:Implications in pulmonary hypertension Physiological,pathophysiological and pharmacological regulation[J]. Pharmacol Ther,2021,225:107835.
[15] Maietta V,Reyes-García J,Yadav VR,et al. Cellular and molecular processes in pulmonary hypertension[J]. Adv Exp Med Biol,2021,1304:21-38.
[16] Cardouat G,Guibert C,Freund-Michel V. [The expression and role of nerve growth factor (NGF) in pulmonary hypertension][J]. Rev Mal Respir,2020,37(3):205-209.
[17] Cai Z,Li J,Zhuang Q,et al. MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways[J]. Exp Mol Med,2018,50(4):1-11.
[18] Sun LY,Cai ZY,Pu J,et al. 5-Aminosalicylic acid attenuates monocrotaline-induced pulmonary arterial hypertension in rats by increasing the expression of Nur77[J]. Inflammation,2017,40(3):806-817.
[19] Welch CL,Chung WK. Channelopathy genes in pulmonary arterial hypertension[J]. Biomolecules,2022,12(2):265.
[20] Luo Y,Teng X,Zhang L,et al. CD146-HIF-1αhypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension[J]. Nat Commun,2019,10(1):3551.
[21] Yang K,Wang J,Lu W. Bone morphogenetic protein signalling in pulmonary hypertension:advances and therapeutic implications[J]. Exp Physiol,2017,102(9):1083-1089.
[22] Hobro AJ,Smith NI. Vibrational spectroscopic imaging of pathogens,microorganisms,and their interactions with host systems[J]. Optics Communications,2018,422:75-84.
[23] Marri PR,Stern DA,Wright AL,et al. Asthma-associated differences in microbial composition of induced sputum[J]. J Allergy Clin Immunol,2013,131(2):346-352. e1-3.
[24] Zhang C,Zhang T,Lu W,et al. Altered airway microbiota composition in patients with pulmonary hypertension[J]. Hypertension,2020,76(5):1589-1599.
[25] Liu NN,Ma Q,Ge Y,et al. Microbiome dysbiosis in lung cancer:from composition to therapy[J]. NPJ Precis Oncol,2020,4(1):33.
[26] Ubags NDJ,Marsland BJ. Mechanistic insight into the function of the microbiome in lung diseases[J]. Eur Respir J,2017,50(3):1602467.
[27] Sabatel C,Radermecker C,Fievez L,et al. Exposure to bacterial CpG DNA protects from airway allergic inflammation by expanding regulatory lung interstitial macrophages[J]. Immunity,2017,46(3):457-473.
[28] Ma R,Cheng L,Song Y,et al. Altered lung microbiome and metabolome profile in children with pulmonary arterial hypertension associated with congenital heart disease[J]. Front Med (Lausanne),2022,9:940784.
[29] Tang WHW,Li DY,Hazen SL. Dietary metabolism,the gut microbiome,and heart failure[J]. Nat Rev Cardiol,2019,16(3):137-154.
[30] Marques FZ,Mackay CR,Kaye DM. Beyond gut feelings:how the gut microbiota regulates blood pressure[J]. Nat Rev Cardiol,2018,15(1):20-32.
[31] Sharma RK,Yang T,Oliveira AC,et al. Microglial cells impact gut microbiota and gut pathology in angiotensin II-induced hypertension[J]. Circ Res,2019,124(5):727-736.
[32] Sharma RK,Oliveira AC,Yang T,et al. Pulmonary arterial hypertension-associated changes in gut pathology and microbiota[J]. ERJ Open Res,2020,6(3):00253-2019.
[33] Kim S,Rigatto K,Gazzana MB,et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension[J]. Hypertension,2020,75(4):1063-1071.
[34] Hong W,Mo Q,Wang L,et al. Changes in the gut microbiome and metabolome in a rat model of pulmonary arterial hypertension[J]. Bioengineered,2021,12(1):5173-5183.
[35] Sanada TJ,Hosomi K,Shoji H,et al. Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model[J]. Pulm Circ,2020,10(3):2045894020929147.
[36] Thenappan T,Khoruts A,Chen Y,et al. Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?[J]. Am J Physiol Heart Circ Physiol,2019,317(5):H1093-H1101.
[37] Bell JS,Spencer JI,Yates RL,et al. Invited Review:From nose to gut-the role of the microbiome in neurological disease[J]. Neuropathol Appl Neurobiol,2019,45(3):195-215.
[38] Moutsoglou DM. 2021 American Thoracic Society BEAR cage winning proposal:microbiome transplant in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2022,205(1):13-16.
[39] Qiu H,He Y,Ouyang F,et al. The role of regulatory T cells in pulmonary arterial hypertension[J]. J Am Heart Assoc,2019,8(23):e014201.
[40] Thenappan T,Chan SY,Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension [J]. Am J Physiol Heart Circ Physiol,2018,315(5):H1322-H1331.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(5):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(5):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]